Clinical trials: Histological Response
Peripheral T-cell Lymphoma
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in…
- Trial name
- NCT01420679
- Testing
- Pralatrexate Injection
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 21 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Polycythemia Vera, ET (Essential Thrombocythemia)
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV)…
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET)
- Trial name
- NCT07362225
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- MPN Research Foundation
Carcinoma, Renal Cell
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.
- Trial name
- REMISCAN (NCT00842790)
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sarcoma
Advanced MR Imaging in Sarcoma Patients
We intend to investigate the clinical application of two emerging imaging modalities for which the technical capability is currently in place at Mayo Clinic.
- Trial name
- NCT02705391
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Melanoma
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors…
- Trial name
- IMMUSPHINX (NCT03627026)
- Testing
- Blood samples will be collected at different time points:
- Where
- 2 sites in France
- Volunteers
- 78 people
- Sponsor
- Institut Claudius Regaud
Leukemia
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01360125
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 310 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Large B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
- Trial name
- NCT05257018
- Testing
- R-CDOP+intrathecal MTX
- Where
- 2 sites in China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Oral Cavity Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction
- Trial name
- NeoNivo (NCT03843515)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma (Skin)
Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics
This study will investigate the effects of gut microbiome diversity (richness in terms of many bacterial species in the gut) on responses and side effects of immunotherapy in advanced melanoma patients.
- Trial name
- PRIMM (NCT03643289)
- Where
- 5 sites in United Kingdom
- Volunteers
- 450 people
- Sponsor
- East and North Hertfordshire NHS Trust
Myelodysplastic Syndrome
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a rare, potentially serious bone marrow disease. Currently available treatments for MDS have been only somewhat beneficial.
- Trial name
- NCT00466843
- Testing
- Antithymocyte globulin (ATG), Prednisone
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Office of Rare Diseases (ORD)
Chronic Myeloid Leukemia
Effect of Pharmacogenetics on Imatinib Plasma Level and Response
Imatinib, the tyrosine kinase inhibitor, is used for treatment of Philadelphia positive chronic myeloid leukemia. Despite its efficacy and favorable pharmacokinetic profile, there is a large inter-individual variability in…
- Trial name
- NCT03262974
- Testing
- PCR, HPLC-UV
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Metastatic Urothelial Carcinoma
Urine Omics Predicting IO Therapy Responses in mUC Patients
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.
- Trial name
- NCT04641936
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Chronic Phase Chronic Myeloid Leukemia
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
In this phase I pilot study, it is planned to investigate the feasibility and safety of adding an interferon therapy to an preexisting imatinib treatment in patients with chronic phase chronic myeloid leukaemia.
- Trial name
- NCT01933906
- Testing
- P1101
- Where
- 4 sites in Austria
- Volunteers
- 12 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Metastatic Seminoma
Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma
This study evaluated the safety, efficacy and toxicity of carboplatin area under the curve (AUC)-10 in metastatic seminoma to see if, by using fluoro-deoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) to…
- Trial name
- Car-PET (NCT02272816)
- Testing
- Carboplatin AUC-10
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Barts & The London NHS Trust
Metastatic Melanoma
Study of Immune Responses in Patients With Metastatic Melanoma
In this study, anti-OX40 will be given to patients with melanoma to find out how the immune system responds to treatment with anti-OX40.
- Trial name
- NCT01416844
- Testing
- anti-OX40
- Where
- United States
- Sponsor
- Providence Health & Services
Refractory Solid Tumors, Lymphoma
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
This is a Phase I continuous infusion study designed to explore if constant concentration over time adds to the effectiveness of terameprocol without increasing toxicity. It will also explore weekly dosing as an option.
- Trial name
- NCT00664586
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Erimos Pharmaceuticals
Chronic Myeloid Leukemia, Chronic Phase
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
The purpose of the present study is to determine the rate of successful treatment-free remission (TFR) within the first 52 weeks following cessation of ponatinib treatment in patients who achieved MR4.
- Trial name
- ResToP (NCT04160546)
- Testing
- Ponatinib 15 MG, Acetylsalicylic acid 100 MG
- Where
- 13 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
This multicenter retrospective-prospective cohort study evaluates predictive biomarker and tissue-pathology features for response to PD-1 inhibitor-based therapy in patients with squamous cell carcinoma (SCC).
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
- Trial name
- PB-PD1R-SCC (NCT07147361)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Oral Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
Backgrounds Squamous cell carcinoma of the oral cancer (OSCC) is the sixth most common malignancy. Surgery is the mainstay of treatment for oral cancers.
- Trial name
- NCT04137627
- Testing
- Melatonin 20 MG Oral Capsule
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Indonesia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.